A Long-term Follow-up Study of Patients Who Received VOR33
Recruiting at 10 trial locations
Age: Any Age
Sex: Any
Trial Phase: Academic
Sponsor: Vor Biopharma
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 1 JurisdictionThis treatment is already approved in other countries
Trial Summary
What is the purpose of this trial?
VOR33 long-term follow-up (LTFU) study
Eligibility Criteria
Inclusion Criteria
Has received any part of or all of a VOR33 infusion
Timeline
Screening
Participants are screened for eligibility to participate in the trial
2-4 weeks
Treatment
Participants receive the VOR33 infusion as part of the initial study
Not specified
Long-term Follow-up
Participants are monitored for long-term safety and efficacy of VOR33
15 years
Treatment Details
Interventions
- VOR33
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Observational Cohort 1Experimental Treatment1 Intervention
All patients who have received any part of or all of a VOR33 genome-edited hematopoietic stem and progenitor cell therapy product.
VOR33 is already approved in United States for the following indications:
Approved in United States as trem-cel for:
- Acute Myeloid Leukemia (AML)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Vor Biopharma
Lead Sponsor
Trials
3
Recruited
80+
Other People Viewed
By Subject
By Trial
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.